CSIMarket
 
Lantheus Holdings Inc   (LNTH)
Other Ticker:  
 
 
Price: $115.4500 $7.47 6.918%
Day's High: $118.21 Week Perf: 4.87 %
Day's Low: $ 108.67 30 Day Perf: 7.11 %
Volume (M): 1,720 52 Wk High: $ 126.89
Volume (M$): $ 198,597 52 Wk Avg: $80.57
Open: $109.00 52 Wk Low: $50.20



 Market Capitalization (Millions $) 8,151
 Shares Outstanding (Millions) 71
 Employees 834
 Revenues (TTM) (Millions $) 1,437
 Net Income (TTM) (Millions $) 428
 Cash Flow (TTM) (Millions $) 343
 Capital Exp. (TTM) (Millions $) 108

Lantheus Holdings Inc
Lantheus Holdings Inc.
is a publicly traded diagnostics and imaging company based in North Billerica, Massachusetts.
It was formerly known as Bristol-Myers Squibb Medical Imaging and was spun off as a separate entity in 2008.
Lantheus Holdings specializes in the development, production, and distribution of diagnostic imaging agents used in medical imaging, such as ultrasound, nuclear medicine, and magnetic resonance imaging (MRI).
The company's flagship product is DEFINITY, an echocardiography agent that enhances the accuracy and clarity of ultrasound images of the heart.
The company has a global presence, with offices and facilities located in the United States, Canada, Australia, and Puerto Rico.
It also has a robust network of distribution partners and collaborations with other healthcare companies, academic institutions, and research organizations working toward advancing diagnostic imaging.
In recent years, Lantheus Holdings has expanded its product portfolio through acquisitions and partnerships with other companies, including the acquisition of Progenics Pharmaceuticals in 2019.
The company's primary focus is on improving patient outcomes through the development and commercialization of innovative diagnostic agents and technologies.


   Company Address: 201 Burlington Road, South Building Bedford, 1730 MA
   Company Phone Number: 671-8001   Stock Exchange / Ticker: NASDAQ LNTH


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY        6.1% 
GEHC        2.02% 
LLY   -5.54%    
TMO        1.75% 
• View Complete Report
   



Management Announcement

Lantheus Celebrates CMS Rule Enhancement for Diagnostic Radiopharmaceuticals Translates to Better Patient Access and Care

Published Mon, Nov 4 2024 12:31 PM UTC

In a significant move for the healthcare landscape, Lantheus Holdings, Inc. has expressed its commendation for the Centers for Medicare & Medicaid Services (CMS) recent rule concerning the calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS). The announcement, made on November 4, 2024, signals a pivotal recognition of specialized diagnostic radio...

Clinical Study

Advancements in Prostate Cancer Management A Radiographic Breakthrough from Lantheus SPLASH Trial

Published Sun, Sep 15 2024 12:45 PM UTC

In a pivotal moment for prostate cancer therapy, Lantheus Holdings, Inc. has presented compelling findings from the Phase 3 SPLASH trial at the 2024 European Society for Medical Oncology (ESMO) Congress. This landmark trial focused on men with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). By achieving its primary endpoint of significant improvement ...

Product Service News

Lantheus Acquires NAV-4694, a Next-Generation Amyloid PET Imaging Agent for Alzheimers Disease

Published Mon, Jul 15 2024 12:30 PM UTC

Lantheus Acquires NAV-4694, Enhancing Alzheimer's Diagnostic ToolboxLantheus, a leading provider of diagnostic medical imaging agents, announced its acquisition of NAV-4694, a next-generation amyloid PET imaging agent designed to detect Alzheimer's disease. This strategic acquisition is poised to enhance Lantheus' diagnostic capabilities and broaden its pipeline, strengthen...

Stocks on the Move

Lantheus Holdings Inc Overcomes Initial Market Performance Slump with Favorable Analyst Ratings and CMS Proposed Rule on Radiopharmaceutical Reimbursement

Published Sat, Jul 13 2024 1:48 PM UTC

Lantheus Holdings Inc Shares Trail Performance of Entire Market: An Analysis of Recent EventsIn this week, Lantheus Holdings Inc shares have been trailing the overall performance of the market. This could be attributed to several recent events surrounding the company. Let's analyze these events to gain a better understanding of their impact on Lantheus Holdings Inc's market ...

Clinical Study

Navigating New Frontiers in Oncology Lantheus Expands Precision Medicine Portfolio with GRPR-Targeted Innovations for...

Published Thu, Jun 27 2024 11:05 AM UTC

'Harnessing Precision Medicine: Lantheus Expands Therapeutic and Diagnostic Horizons in Prostate and Breast Cancer'''The fight against cancer continues to evolve with remarkable innovations, bringing new hope for improved diagnostics and treatments. In a bold and strategic move, Lantheus, a leader in medical imaging, has announced the acquisition of global rights to Life Mol...







Lantheus Holdings Inc's Segments
Product revenue, net    99.66 % of total Revenue
License and royalty revenues    0.34 % of total Revenue
Total radiopharmaceutical oncology    69.34 % of total Revenue
PYLARIFY    69.34 % of total Revenue
Total precision diagnostics    28.45 % of total Revenue
DEFINITY    19.82 % of total Revenue
TechneLite    7.15 % of total Revenue
Other precision diagnostics    1.48 % of total Revenue
Strategic partnerships and other revenue    2.21 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com